- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06512883
Próba zbadania Benralizumabu u dzieci z chorobami eozynofilowymi (CLIPS)
Faza 3, otwarte badanie oceniające bezpieczeństwo, farmakokinetykę i skuteczność benralizumabu u dzieci z chorobami eozynofilowymi (CLIPS)
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
This study is open-label, multicentre, basket study to evaluate the safety, PK, pharmacodynamic (PD), efficacy, and immunogenicity of repeat dosing of benralizumab subcutaneous (SC) every 4 weeks (Q4W) in male and female children with rare eosinophilic diseases.
Paediatric participants with eosinophilic granulomatosis with polyangiitis (EGPA) will be enrolled in the first cohort.
Paediatric participants with hypereosinophilic syndrome (HES) will be enrolled in the second cohort. Additional cohorts in other eosinophilic diseases may be added in future protocol amendments.
The study consists of 3 periods:
- Screening period: 1 to 4 weeks
- Open-label treatment period: 52 weeks
- Open-label extension period: at least 52 weeks (plus safety follow-up [SFU] weeks after last investigational product [IP] administration)
All eligible participants will receive benralizumab SC Q4W during the 52-week open-label treatment period.
All participants who complete the 52-week open-label treatment period on IP will be offered the opportunity to continue into an extension period. The extension period is intended to allow each participant at least an additional one year of treatment with benralizumab.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 3
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: AstraZeneca Clinical Study Information Center
- Numer telefonu: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Lokalizacje studiów
-
-
-
São Paulo, Brazylia, 01232-010
- Rekrutacyjny
- Research Site
-
-
-
-
-
Lille, Francja, 59037
- Rekrutacyjny
- Research Site
-
Montpellier, Francja, 34295
- Zawieszony
- Research Site
-
-
-
-
-
Rotterdam, Holandia, 3015 GD
- Rekrutacyjny
- Research Site
-
-
-
-
-
Ahmedabad, Indie, 380052
- Rekrutacyjny
- Research Site
-
-
-
-
-
Petah Tikva, Izrael, 49202
- Rekrutacyjny
- Research Site
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G1X8
- Rekrutacyjny
- Research Site
-
-
-
-
-
Guadalajara, Meksyk, 44620
- Rekrutacyjny
- Research Site
-
-
-
-
-
Kielce, Polska, 25-734
- Rekrutacyjny
- Research Site
-
Warsaw, Polska, 04-730
- Jeszcze nie rekrutacja
- Research Site
-
-
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Rekrutacyjny
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45229
- Rekrutacyjny
- Research Site
-
Highland Hills, Ohio, Stany Zjednoczone, 44106-2624
- Rekrutacyjny
- Research Site
-
-
-
-
-
Altındağ, Turcja (Türkiye), 06230
- Rekrutacyjny
- Research Site
-
Istanbul, Turcja (Türkiye), 34093
- Rekrutacyjny
- Research Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
All Cohorts:
- Male or female participants must be aged 6 to < 18 years of age at the time of signing the assent form and their caregiver signing the informed consent form.
- Body weight greater than (>=) 15 kilograms (kg).
EGPA Cohort:
- Therapy with corticosteroids: The prescribed dose of oral corticosteroids (OCS) (greater than [>] 0.1 milligrams per kilogram per day (mg/kg/day), max dose of 50 milligrams per day (mg/day) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).
- Immunosuppressive therapy: If receiving immunosuppressive therapy, the dosage must be stable for at least 4 weeks prior to baseline (Visit 2).
HES Cohort:
- Documented HES diagnosis, defined as history of persistent eosinophilia >1500 cells/µL without secondary cause on 2 examinations ≥1 month apart and evidence of eosinophil-mediated organ involvement.
- Symptomatic active HES, or history of a prior flare, or considered eligible based on disease severity per investigator judgement.
- AEC ≥1000 cells/µL at screening (Visit 1).
- Documented negative testing for Fip1-like 1 gene fused with the platelet-derived growth factor receptor alpha gene (FIP1L1-PDGFR) fusion tyrosine kinase gene translocation.
Exclusion Criteria:
All Cohorts:
- Any current malignancy or history of malignancy.
- History of anaphylaxis to any biologic therapy or vaccine.
- Known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities.
- Previous receipt of benralizumab in an interventional clinical study.
EGPA Cohort:
- Diagnosed with granulomatosis with polyangiitis (previously known as Wegener'granulomatosis) or microscopic polyangiitis.
- EGPA relapse: any deterioration in EGPA and/or organ-threatening EGPA that per Investigator judgement renders participants unstable in their EGPA within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2).
- Life-threatening EGPA: imminently life-threatening EGPA disease within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2), as per Investigator judgement.
HES Cohort:
- Life-threatening HES or HES complications, as judged by the investigator.
- Hypereosinophilia of unknown significance (HE-US).
- Diagnosis of systemic mastocytosis.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: EGPA/HES Cohort: Benralizumab
Participants with greater than or equal to (>=) 35 kg weight will receive benralizumab dose-1 and participants with less than (<) 35 kg weight will receive benralizumab dose-2 as SC injection Q4W during the 52-week treatment period. All participants who complete the 52-week treatment period will be offered the opportunity to continue into an extension period. |
Benralizumab will be administered as SC injection on Q4W.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Participants with Adverse Events (AEs)
Ramy czasowe: From screening (Week -4 to -1) until Week 52
|
The safety and tolerability of benralizumab will be evaluated. |
From screening (Week -4 to -1) until Week 52
|
|
Serum Concentrations of Benralizumab
Ramy czasowe: Weeks 0, 12, 24, 25, 36, and 52
|
The PK of benralizumab will be evaluated. |
Weeks 0, 12, 24, 25, 36, and 52
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
EGPA Cohort: Percentage of Participants with Remission at Week 24
Ramy czasowe: At Week 24
|
Remission defined as Paediatric Vasculitis Activity Score (PVAS) = 0 and oral corticosteroid (OCS) intake less than or equal to (<=) 0.1 mg/kg/day. |
At Week 24
|
|
Number of Participants with Positive Antidrug Antibody (ADA)
Ramy czasowe: Weeks 0, 12, 24, 36, 48, and 52
|
The immunogenicity of benralizumab will be evaluated. |
Weeks 0, 12, 24, 36, 48, and 52
|
|
Change From Baseline in Peripheral Blood Eosinophil Count
Ramy czasowe: From Baseline to Weeks 0, 12, 24, 36, 52
|
The PD effect of benralizumab on peripheral blood eosinophil count will be evaluated. |
From Baseline to Weeks 0, 12, 24, 36, 52
|
|
EGPA Cohort: Time to First EGPA Relapse
Ramy czasowe: Up to 52 weeks
|
The efficacy of benralizumab on time to first relapse will be assessed. EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) Active vasculitis (PVAS > 0); OR b) Worsening of asthma symptoms (based on Asthma Control Questionnaire - Interviewer Administered [ACQ-IA]); OR c) Active nasal and/or sinus disease with worsening in at least one sino-nasal symptom question warranting any of the following: 1) Increase OCS; OR 2) Increase/addition of immunosuppressive medication; OR 3) Hospitalisation related to EGPA worsening. |
Up to 52 weeks
|
|
HES Cohort: Time to first HES worsening/flare
Ramy czasowe: Up to 52 weeks
|
The effect of benralizumab on HES worsening/flares will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Percentage of participants who experience a HES worsening/flare
Ramy czasowe: Up to 52 weeks
|
The effect of benralizumab on HES worsening/flares will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Number of HES worsening/flares (annualised rate/year)
Ramy czasowe: Up to 52 weeks
|
The effect of benralizumab on HES worsening/flares will be evaluated. The annualised HES worsening/flare rate will be calculated as follows: The total number of flares *365.25 / total duration of follow-up in the treatment period (days). |
Up to 52 weeks
|
|
HES Cohort: Percentage of Participants requiring an increase in corticosteroid dose
Ramy czasowe: Up to 52 weeks
|
The effect of benralizumab on corticosteroid use will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Time to first haematologic relapse
Ramy czasowe: Up to 52 weeks
|
The time to first haematologic relapse will be defined as the time from first dose of IP to the first post baseline visit with Absolute eosinophil count [AEC] ≥ 1000 cells/uL. |
Up to 52 weeks
|
|
HES Cohort: Percentage of Participants with haematologic relapse
Ramy czasowe: Up to 52 weeks
|
The effect of benralizumab on haematologic measures of disease activity will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Percentage of Participants who have AEC < 500 cells/μL for 24 weeks
Ramy czasowe: Up to 52 weeks
|
The effect of benralizumab on haematologic measures of disease activity will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Patient Global Impression of Change (PGI-C) Score
Ramy czasowe: Weeks 12, 24, 36 and 48
|
The effect of benralizumab on participant/caregiver reported measures of disease severity and health status will be assessed. The PGI-C instrument captures the participant's overall evaluation of response to treatment, and rated on a 7-point PGI-C scale ranging from 1 ('much better') to 7 ('much worse'). |
Weeks 12, 24, 36 and 48
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby naczyniowe
- Choroby układu krążenia
- Choroby Autoimmunologiczne
- Choroby układu odpornościowego
- Choroby skórne
- Choroby limfatyczne
- Zaburzenia limfoproliferacyjne
- Choroby skóry, naczyniowe
- Zapalenie naczyń
- Zapalenie naczyń związane z przeciwciałami przeciwko cytoplazmie neutrofili
- Ziarniniak
- Układowe zapalenie naczyń
- Choroby skóry i tkanki łącznej
- Choroby hemowe i limfatyczne
- Zespół Churga-Straussa
- Benralizumab
Inne numery identyfikacyjne badania
- D3255C00004
- 2023-508533-14-00 (Inny identyfikator: EU CT)
- EMEA-001214-PIP09-21-M02(EGPA) (Inny identyfikator: Paediatric Investigational Plan Number)
- EMEA-001214-PIP04-19-M02 (HES) (Inny identyfikator: Paediatric Investigational Plan Number)
- 2023 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via there quest portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Ramy czasowe udostępniania IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Kryteria dostępu do udostępniania IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .